SGS Life Science Services opens a Center of Excellence for Biophysical Analysis in the UK.
SGS Life Science Services has completed the development of a Center for Excellence for biophysical analysis of biopharmaceutical products in its SGS M-Scan facility in Wokingham, the United Kingdom.
The biophysical analysis group is lead by Dr.Iñigo Rodriguez-Mendieta, who along with his team, provides expertise in higher order structure analysis. The team can perform aggregation analysis, secondary/tertiary structural analysis, and thermal stability assessment and comparison. The new center complements the company's recent investment, announced in March 2013, to develop integrated formulation and stability testing services at the Wokingham facility, slated for completion in the fourth quarter 2013 and to be fully validated by early 2014.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.